Table 1.

Evaluation of six different immunologic parameters in patients treated with anti-CTLA-4

Patients with bladder cancer who received anti-CTLA-4 therapy
PatientPretreatmentPosttreatment (dose 1)Posttreatment (dose 2)
% ICOS+ CD4 T cells
11.413.58.7
21.99.721.7
32.89.740.1
41.914.26.4
54.216.627.8
62.913.56.6
% HLA-DR+ CD4 T cells
13.56.53.4
21.23.01.2
31.98.35.2
% CD25+ CD4 T cells
16.810.918.8
230.731.338.5
343.037.438.5
% CD4 T cells
152.751.351.5
232.140.543.5
341.037.123.7
446.945.045.4
522.441.735.3
629.635.734.3
% CD8 T cells
111.56.710.8
212.015.322.7
311.510.55.8
416.113.226.0
56.16.85.8
69.38.97.5
Absolute lymphocyte count (k/μL)
12.343.171.86
23.514.635.13
31.881.910.95
43.942.824.49
50.761.131.08
60.902.833.21